Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

Metabolic changes promoting cell survival are involved in metastatic melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant melanoma cells, we explored the role of FASN, an enzyme involved in lipogenesis overexpressed in metastatic melanoma. Resistant melanoma ce...

Full description

Bibliographic Details
Main Authors: Serena Stamatakos, Giovanni Luca Beretta, Elisabetta Vergani, Matteo Dugo, Cristina Corno, Elisabetta Corna, Stella Tinelli, Simona Frigerio, Emilio Ciusani, Monica Rodolfo, Paola Perego, Laura Gatti
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
FASN inhibitor
vemurafenib
resistance
melanoma
DHCR24 inhibitor
Online Access:https://www.mdpi.com/2072-6694/13/9/2284

Similar Items

Similar Items